You are here: Industry Insights > Market News > Brazil's Anvisa suspends Covaxin shot's emergency use application

Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!

Note: You can unsubscribe from the alerts at any time.

Advertising

New Products

3-Bromo-4-fluorobenzaldehyde

5-Methyl-1,3,4-oxadiazol2(3H)-one

4-Amino-6-methyl-3 oxo2,3, 4,5-tetrahydro 1.2.4-triazine hydrochloride

4-Acetylamino-6-methyl -3-oxo-2,3,4,5-tetrahydro-1,2,4-triazine

3-Pyridinecarboxaldehyde

Ethyl 3 Fluorobenzoate

Brazil's Anvisa suspends Covaxin shot's emergency use application

firstwordpharmaJuly 01, 2021

Tag: brazil , Covaxin , COVID-19 , Vaccine

Favorites

Brazil's health regulator has suspended Covaxin's emergency-use application, which was filed by an intermediary on behalf of the COVID-19 vaccine's developer Bharat Biotech, as reported in This is Money.

Brazil's Anvisa suspends Covaxin shot's emergency use application

Anvisa said the intermediary, Precisa, did not submit, or only partially submitted, mandatory and essential documents for the vaccine.

Covaxin has become highly controversial in Brazil over allegations of "irregularities" in the government's efforts to buy 20 million doses.

Previous:Letting children catch Covid may be safer than giving them vaccine, say experts

Next:Tenaya Therapeutics Announces New Appointments to Leadership Team

BioPharmaSpec Announces Three New Facilities in Freiburg, Bergamo and Vilnius

Biotech NewswireNovember 20, 2024

BioPharmaSpec, the leading global Contract Research Organization (CRO) for Discovery and Preclinical Characterization of Biopharmaceuticals, has officially announced three new European facilities.

Rona Therapeutics Presented Positive Phase 1 Results of RN0191, a Novel siRNA Therapy Targeting PCSK9, at the 2024 American Heart Association (AHA) Scientific Sessions

PR NEWSWIRENovember 20, 2024

AI in Pharmacovigilance: Predicting & Preventing Drug Risks

Nurah EkhlaqueNovember 19, 2024

Brazil's Anvisa suspends Covaxin shot's emergency use application | Pharmasources.com

InnoCare Announces First Subject Dosed in the Phase III Registrational Trial of TYK2 Inhibitor ICP-332 for the Treatment of Atopic Dermatitis in China

PharmaSourcesNovember 15, 2024

InnoCare Announces First Subject Dosed in the Phase III Registrational Trial of TYK2 Inhibitor ICP-332 for the Treatment of Atopic Dermatitis in China

You may like
More>>

Recombinant Hepatitis B Vaccine (Hansenula polymorpha)

Inactivated flu vaccine

Influenza Vaccine(Split Virion),Inactivated manufactured by Hualan Bio

Hualan Biological Meningococcal Polysaccharide Vaccine Group ACYW135

Influenza A (H1N1) Vaccine, (Split, Inactivated)

Influenza Vaccine in Syringe

Influenza Vaccine(Split Virion),Inactivated of Hualan Bio

Rabies Vaccine(Vero Cell)for Human use

Hualan-Biological Recombinant Hepatitis B Vaccine (Hansenula polymorpha)with High purity and good s

Hualan-Inactivated Influenza Vaccine(Split Virion) manufactured by Hualan Bio

Brazil's Anvisa suspends Covaxin shot's emergency use application

Related News

BioPharmaSpec Announces Three New Facilities in Freiburg, Bergamo and Vilnius

Rona Therapeutics Presented Positive Phase 1 Results of RN0191, a Novel siRNA Therapy Targeting PCSK9, at the 2024 American Heart Association (AHA) Scientific Sessions

AI in Pharmacovigilance: Predicting & Preventing Drug Risks

InnoCare Announces First Subject Dosed in the Phase III Registrational Trial of TYK2 Inhibitor ICP-332 for the Treatment of Atopic Dermatitis in China

You may likeMore>>

You may like
More>>